Patients' knowledge about psoriasis and comorbidities; their participation in treatment decisions.
Conclusion: The results of this study showed that majority of patients with psoriasis are not aware of the increased risk of comorbid diseases and do not have enough knowledge about psoriasis. PMID: 31257954 [PubMed - as supplied by publisher]
Study objectives: Many patients with psoriasis (PSO) experience comorbidities such as psoriatic arthritis, cardiovascular disease, inflammatory bowel disease and depression, which can make treatment and management challenging. We assessed whether an online, virtual patient simulation (VPS) activity could improve the competence of dermatologists in managing patients with PSO and comorbidities.
Background: Disease-related depression has been reported in those with chronic skin disorders (CSDs). We therefore aimed to determine the prevalence of depression in 4 selected CSDs [acne, psoriasis, atopic dermatitis (AD) and alopecia areata (AA)], each considered to be one of the psycho-physiologic disorders associated with depression.
Introduction: Anxiety and depression are comorbidities associated with psoriasis. The total healthcare cost reduction associated with improvements in anxiety and depression in psoriasis patients derived from newer biologic treatments is unknown.
Psoriasis is a chronic, systemic, inflammatory disease involving skin, nails, and joints. Nail psoriasis may lead to many difficulties in daily activities including work and impairment in quality of life and may also be the cause of severe pain, anxiety and depression. A 66-year-old woman with a history of seronegative arthritis receiving methotrexate presented with severe ungual dystrophy affecting all 20 nails. Clinical examination revealed subungual hyperkeratosis, salmon patches, periungual erythema, onycholysis and nail crumbling.
Mental health more affected by cyber-bullying, less sleep and physical activity Related items fromOnMedica Screen time - a moral panic for the 21st century? Brain and cognitive changes found after regular GHB use Goth teens at higher risk of depression and self-harm Psoriasis linked to raised risk of many mental health problems Child mental health linked to families who struggle
PMID: 31319437 [PubMed - as supplied by publisher]
Authors: Reich K, Foley P, Han C, McElligott S, Muser E, Li N, Armstrong AW Abstract Purpose: To evaluate the impact of guselkumab on work productivity, including absenteeism and presenteeism, in psoriasis patients with and without depression/anxiety. Methods: VOYAGE 2 is a randomized, double-blind, placebo-controlled, and comparator-controlled, phase 3 trial that compared guselkumab with adalimumab in patients with moderate-to-severe psoriasis. Absenteeism was evaluated among patients who reported that their skin prevented work/study based on the Dermatology Life Quality Index (DLQI) work/study domain (score = 3) ...
Conclusions: The prevalence of comorbidities and high rate of IMM prescriptions demonstrate the impact of AD on quality of life. The frequency of OCS prescribing in AD patients treated with IMMs suggests a lack of disease control with existing therapies, and an unmet need for safe and effective targeted agents for long-term disease control. PMID: 31305182 [PubMed - as supplied by publisher]
Conditions: Psoriasis; Depression Intervention: Sponsor: University Hospital, Clermont-Ferrand Not yet recruiting
Authors: Cai Q, Teeple A, Wu B, Muser E Abstract Objective: To describe the prevalence and costs of anxiety and depression among moderate-to-severe psoriasis (PsO) patients in a commercially-insured US population. Methods: The IBM® MarketScan® Commercial database was used to select adults with moderate-to-severe PsO (≥1 PsO diagnosis and ≥1 systemic or biologic medication) within each calendar year from 2014-2016. Adults with no diagnosis of PsO or similar disorders were randomly selected (2014-2016) and matched 1:1 to PsO patients to compare the prevalence of anxiety and depression each year. Moderat...